| Dr Cassiana Euzebio Bittencourt, MD | |
|
101 The City Dr S, Orange, CA 92868 | |
| (714) 456-5439 | |
| Not Available |
| Full Name | Dr Cassiana Euzebio Bittencourt |
|---|---|
| Gender | Female |
| Speciality | Pathology - Medical Microbiology |
| Location | 101 The City Dr S, Orange, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154612281 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZM0300X | Pathology - Medical Microbiology | A143867 (California) | Primary |
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558311811 PECOS PAC ID: 1951201185 Enrollment ID: O20040112000598 |
News Archive
InTouch Health® announced today that it has surpassed 100,000 clinical sessions performed through its Remote Presence telemedicine network. InTouch Health provides comprehensive telehealth solutions that allow physicians to remotely perform complete and real-time consults with hospital patients.
This post in the Center for Global Health Policy's "Science Speaks" blog reports on a presentation at the Union World Conference on Lung Health in France on Saturday by Evelyne Kibuchi, a senior tuberculosis (TB) advocacy officer at the Kenya AIDS NGOs Consortium (KANCO), writing, "HIV stakeholders have been slow to embrace and adopt TB interventions, Kibuchi said, and resources for co-infection activities are modest.
Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that its DiscoveryMAP platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, according to a study published by the journal Circulation.
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cassiana Euzebio Bittencourt, MD 101 The City Dr S, Orange, CA 92868-3201 Ph: (714) 456-6868 | Dr Cassiana Euzebio Bittencourt, MD 101 The City Dr S, Orange, CA 92868 Ph: (714) 456-5439 |
News Archive
InTouch Health® announced today that it has surpassed 100,000 clinical sessions performed through its Remote Presence telemedicine network. InTouch Health provides comprehensive telehealth solutions that allow physicians to remotely perform complete and real-time consults with hospital patients.
This post in the Center for Global Health Policy's "Science Speaks" blog reports on a presentation at the Union World Conference on Lung Health in France on Saturday by Evelyne Kibuchi, a senior tuberculosis (TB) advocacy officer at the Kenya AIDS NGOs Consortium (KANCO), writing, "HIV stakeholders have been slow to embrace and adopt TB interventions, Kibuchi said, and resources for co-infection activities are modest.
Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that its DiscoveryMAP platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, according to a study published by the journal Circulation.
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
› Verified 3 days ago
Qun Wang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S Bldg 1, Orange, CA 92868 Phone: 714-456-6141 | |
Richard S Newman, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Arjun Tudi Reddy, MD, MBA Pathology Medicare: Not Enrolled in Medicare Practice Location: 101 The City Dr S Rm 3003, Orange, CA 92868 Phone: 714-506-0737 | |
Xiaohui S Zhao, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Dr. Sindhuja Sivanandham, MBBS Pathology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S Rm 3003, Orange, CA 92868 Phone: 714-456-8888 | |
Navneet Narula, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 |